Table 2 AEs in patients receiving bilastine 20 mg in clinical trials

Kuna P et al. [24]

683

SAR

Any 24.7%

14 days

Headache 10.6%

Somnolence 1.8%

Fatigue 0.4%

Dyspnoea 0.9%

Bachert C et a. [23]

721

SAR

Any 28.3%

14 days

Headache 12.0%

Somnolence 3.9%

Fatigue 2.6%

Sastre J et al. [25]

650

PAR

Any 23.4%

4 weeks

Headache 10.7%

Somnolence 13.7%

Zuberbiert T et al. [29]

525

CIU

Any 30.1%

28 days

Headache 12.1%

Somnolence 5.8%

Fatigue 2.9%